Need more? Try out  Advanced Search (20+ criteria)»

Last Update

is this you? Claim your profile.

Wrong Robert Ring?

Robert H. Ring

Leadership Roles

Wyeth

HQ Phone:  (973) 660-5000

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Wyeth

5 Giralda Farms

Madison, New Jersey,07940

United States

Company Description

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescrip... more.

Find other employees at this company (7,548)

Background Information

Employment History

Chief Science Officer

Autism Speaks Inc


Chief Executive Officer

Vencerx Therapeutics LLC


Adjunct Professor

Drexel University


President

Delivering Scientific Innovation


US government's Interagency Autism Coordinating Committee


Affiliations

Department of Health and Human Services

Member - Interagency Autism Coordinating Committee (IACC)


IACC

Public Member


Society for Neuroscience

Member


American College of Neuropsychopharmacology

Member


International Society for Autism Research Inc

Member


Society of Biological Psychiatry

Member


Interagency

Public Member of the Autism Coordinating Committee, the Federal Advisory Committee


Autism Spectrum News

Chief Science Officer


Education

B.A. double major

Fine Art and Biology

Westmont College


Ph.D.

Molecular Neurobiology

City of Hope


PhD

MIT


PhD

Princeton


Web References(170 Total References)


seriouslyfinance.com

Vencerx Therapeutics, which is focused on advancing treatments for neurodevelopmental disorders, has appointed Dr. Robert H. Ring as CEO and Jeffrey Stevenson as chairman of the board of directors.
Stevenson is managing partner of VSS while Ring is the former CEO of Autism Speaks. PRESS RELEASE NEW YORK, March 31, 2017 /PRNewswire/ - Vencerx Therapeutics, a company focused on advancing treatments for neurodevelopmental disorders, today announced the appointments of Robert H. Ring, Ph.D. as Chief Executive Officer and Jeffrey Stevenson as Chairman of the Board of Directors. Dr. Ring brings significant expertise to Vencerx that includes CNS drug discovery and development, translational research and patient advocacy. His distinguished career spans pharma, non-profit, venture philanthropy and academia, with leadership roles at Pfizer, Wyeth Pharmaceuticals and Autism Speaks among others. "Rob is a recognized leader in the field of autism research and brings years of experience working at the forefront therapeutics development for related neurodevelopmental disorders such as Fragile X. We are pleased to have someone with Rob's experience spearheading our efforts to advance treatments for Fragile X Syndrome and related conditions," said David Malpass, a founder of Vencerx. He brings strong leadership, a stellar investment career and nearly two decades of involvement in advancing the treatment of Fragile X." Regarding Dr. Ring, Mr. Stevenson noted: "Rob is an experienced R&D leader with a unique background in the emerging field of neurodevelopmental disorders that makes him ideally suited to lead our ground-breaking efforts ahead at Vencerx. "I am absolutely thrilled to be joining the team at Vencerx at a moment in time when the field of therapeutics development for rare neurodevelopmental disorders like Fragile X is poised to take off," said Dr. Ring. "The past decade of CNS drug development field has quietly ignored what I see as a massive opportunity to address the diverse unmet needs of families across the autism and neurodevelopmental disorder communities by leveraging the rich diversity of targets and clinical assets pursued, and in many cases abandoned, for other indications. Continued Dr. Ring: "In a short period of time, Vencerx has identified potential partnerships that will quickly establish its initial pipeline around two exciting therapeutic opportunities, both for neurodevelopmental indications like Fragile X. We look forward to sharing more about these lead assets in the coming months. Dr. Ring most recently served as Chief Science Officer of the global nonprofit science foundation Autism Speaks, where he oversaw a science mission credited with over $300 million of funding investments across the autism research community. His leadership tenure was highlighted by the launch of MSSNG, a ground-breaking genomics partnership with Google (now Verily) and the Hospital for Sick Children that has established the field's largest database of genomic sequence information from 10,000 individuals with autism and their families. Ring was also instrumental in starting up DELSIA LLC, the foundation's innovative venture arm that expanded the foundation's philanthropic mission to include innovative investments in commercialization activities by entrepreneurs and small companies. Prior to Autism Speaks, Ring headed the Autism Unit at Pfizer Global Research and Development, considered one of the industry's earliest research divisions dedicated exclusively to the discovery and development of medicines for autism and related neurodevelopmental disorders such as Fragile X. Ring's leadership extended from basic target identification to phase 2 proof-of-concept trials, and he was instrumental in helping shape the commercial strategy for this new therapeutic area. Before Pfizer, Ring worked for over a decade at Wyeth Research in Princeton heading Mood Disorders Research and serving as program leader for numerous drug development programs. A neuroscientist by training, Ring also maintains adjunct faculty appointments in the departments of Psychiatry at the Icahn School of Medicine at Mount Sinai, and Pharmacology & Physiology at Drexel University College of Medicine in Philadelphia. In 2014, Ring was appointed by then HHS Secretary Kathleen Sebelius to serve on the Interagency Autism Coordinating Committee (IACC), and continues his service on the committee after reappointment by Secretary Sylvia M. Burwell in 2015.


seriouslyfinance.com [cached]

Vencerx Therapeutics, which is focused on advancing treatments for neurodevelopmental disorders, has appointed Dr. Robert H. Ring as CEO and Jeffrey Stevenson as chairman of the board of directors.
Stevenson is managing partner of VSS while Ring is the former CEO of Autism Speaks. PRESS RELEASE NEW YORK, March 31, 2017 /PRNewswire/ - Vencerx Therapeutics, a company focused on advancing treatments for neurodevelopmental disorders, today announced the appointments of Robert H. Ring, Ph.D. as Chief Executive Officer and Jeffrey Stevenson as Chairman of the Board of Directors. Dr. Ring brings significant expertise to Vencerx that includes CNS drug discovery and development, translational research and patient advocacy. His distinguished career spans pharma, non-profit, venture philanthropy and academia, with leadership roles at Pfizer, Wyeth Pharmaceuticals and Autism Speaks among others. "Rob is a recognized leader in the field of autism research and brings years of experience working at the forefront Continue reading "Vencerx taps VSS managing partner Stevenson as board chairman"


www.autismspeaks.org [cached]

Rob Ring -- Chief Science Officer
Rob Ring, Chief Science Officer Rob Ring was named Chief Science Officer in June of 2013. Upon his appointment Rob said his first goal would be to "put science to work for our families," and that makes perfect sense given his background. Rob first joined Autism Speaks in June of 2011 as Vice President of Translational Research. In that role, Rob was responsible for the development and implementation of the foundation's expanding translational research portfolio, which serves to accelerate the process of converting scientific breakthroughs and innovations in technology into actual products that address the wide range of unmet needs of the autism community, from healthcare to education to daily living. Rob also serves as President of Delivering Scientific Innovation for Autism (DELSIA), the venture philanthropy arm of Autism Speaks that is helping to facilitate translational activities in the for-profit sector required to develop commercial products that will improve the quality of life and health for individuals with autism. Prior to joining Autism Speaks, Rob served as Senior Director and Head of the Autism Research Unit at Pfizer Worldwide Research and Development in Groton, Conn. There he led the first dedicated research group in the pharmaceutical industry focused specifically on the discovery and development of medicines for neurodevelopmental disorders, specifically ASD. Prior to Pfizer, Rob worked for over 10 years in psychiatric medicines discovery and development at Wyeth Research in Princeton, N.J. Rob earned a B.A. double major in both Fine Art and Biology from Westmont College in Santa Barbara, Calif., and a Ph.D. in Molecular Neurobiology from City of Hope in Southern California. He holds adjunct faculty appointments in the Departments of Psychiatry at Mount Sinai School of Medicine (N.Y.) and Pharmacology and Physiology at Drexel University College of Medicine (Philadelphia).


www.autismspeaks.org

President - Robert H. Ring, Ph.D.
Dr. Ring holds a dual role as DELSIA's president and Autism Speaks' chief science officer, providing overall leadership for Autism Speaks science programs and initiatives. Prior to joining Autism Speaks in 2011, Dr. Ring served as senior director and head of the Autism Research Unit at Pfizer Worldwide Research and Development, in Groton, Conn. Prior to Pfizer, Dr. Ring gained a decade experience in psychiatric drug discovery and development at Wyeth Research, in Princeton, N.J. Dr. Ring holds adjunct faculty appointments in psychiatry at Mount Sinai School of Medicine and in pharmacology and physiology at Drexel University College of Medicine.


www.prnewswire.com [cached]

Vencerx Therapeutics Announces Appointments of Robert H. Ring, Ph.D. as Chief Executive Officer and Jeffrey Stevenson as Chairman of the Board
NEW YORK, March 31, 2017 /PRNewswire/ -- Vencerx Therapeutics, a company focused on advancing treatments for neurodevelopmental disorders, today announced the appointments of Robert H. Ring, Ph.D. as Chief Executive Officer and Jeffrey Stevenson as Chairman of the Board of Directors. Dr. Ring brings significant expertise to Vencerx that includes CNS drug discovery and development, translational research and patient advocacy. His distinguished career spans pharma, non-profit, venture philanthropy and academia, with leadership roles at Pfizer, Wyeth Pharmaceuticals and Autism Speaks among others. Robert H. Ring, Ph.D., Chief Executive Officer of Vencerx Therapeutics Robert H. Ring, Ph.D., Chief Executive Officer of Vencerx Therapeutics "Rob is a recognized leader in the field of autism research and brings years of experience working at the forefront of therapeutics development for related neurodevelopmental disorders such as Fragile X. We are pleased to have someone with Rob's experience spearheading our efforts to advance treatments for Fragile X Syndrome and related conditions," said David Malpass, a founder of Vencerx. Regarding Dr. Ring, Mr. Stevenson noted: "Rob is an experienced R&D leader with a unique background in the emerging field of neurodevelopmental disorders that makes him ideally suited to lead our ground-breaking efforts ahead at Vencerx. Regarding Dr. Ring, Mr. Stevenson noted: "Rob is an experienced R&D leader with a unique background in the emerging field of neurodevelopmental disorders that makes him ideally suited to lead our ground-breaking efforts ahead at Vencerx. "I am absolutely thrilled to be joining the team at Vencerx at a moment in time when the field of therapeutics development for rare neurodevelopmental disorders like Fragile X is poised to take off," said Dr. Ring. "The past decade of CNS drug development field has quietly ignored what I see as a massive opportunity to address the diverse unmet needs of families across the autism and neurodevelopmental disorder communities by leveraging the rich diversity of targets and clinical assets pursued, and in many cases abandoned, for other indications." Continued Dr. Ring: "In a short period of time, Vencerx has identified potential partnerships that will quickly establish its initial pipeline around two exciting therapeutic opportunities, both for neurodevelopmental indications like Fragile X. We look forward to sharing more about these lead assets in the coming months." Dr. Ring most recently served as Chief Science Officer of the global nonprofit science foundation Autism Speaks, where he oversaw a science mission credited with over $300 million of funding investments across the autism research community. His leadership tenure was highlighted by the launch of MSSNG, a ground-breaking genomics partnership with Google (now Verily) and the Hospital for Sick Children that has established the field's largest database of genomic sequence information from 10,000 individuals with autism and their families. Ring was also instrumental in starting up DELSIA LLC, the foundation's innovative venture arm that expanded the foundation's philanthropic mission to include innovative investments in commercialization activities by entrepreneurs and small companies. Prior to Autism Speaks, Ring headed the Autism Unit at Pfizer Global Research and Development, considered one of the industry's earliest research divisions dedicated exclusively to the discovery and development of medicines for autism and related neurodevelopmental disorders such as Fragile X. Ring's leadership extended from basic target identification to phase 2 proof-of-concept trials, and he was instrumental in helping shape the commercial strategy for this new therapeutic area. Before Pfizer, Ring worked for over a decade at Wyeth Research in Princeton heading Mood Disorders Research and serving as program leader for numerous drug development programs. A neuroscientist by training, Ring also maintains adjunct faculty appointments in the departments of Psychiatry at the Icahn School of Medicine at Mount Sinai, and Pharmacology & Physiology at Drexel University College of Medicine in Philadelphia. In 2014, Ring was appointed by then HHS Secretary Kathleen Sebelius to serve on the Interagency Autism Coordinating Committee (IACC), and continues his service on the committee after reappointment by Secretary Sylvia M. Burwell in 2015. Vencerx Therapeutics Announces Appointments of Robert H. Ring, Ph.D. as Chief Executive Officer and Jeffrey Stevenson as Chairman of the Board


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory